SE0102855D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
SE0102855D0
SE0102855D0 SE0102855A SE0102855A SE0102855D0 SE 0102855 D0 SE0102855 D0 SE 0102855D0 SE 0102855 A SE0102855 A SE 0102855A SE 0102855 A SE0102855 A SE 0102855A SE 0102855 D0 SE0102855 D0 SE 0102855D0
Authority
SE
Sweden
Prior art keywords
treatment
sub
pharmaceutically acceptable
acceptable salt
migraine
Prior art date
Application number
SE0102855A
Other languages
English (en)
Swedish (sv)
Inventor
David Lee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102855A priority Critical patent/SE0102855D0/xx
Publication of SE0102855D0 publication Critical patent/SE0102855D0/xx
Priority to CA002456480A priority patent/CA2456480A1/en
Priority to ES02760969T priority patent/ES2274081T3/es
Priority to JP2003522527A priority patent/JP2005503391A/ja
Priority to DE60215525T priority patent/DE60215525T2/de
Priority to EP02760969A priority patent/EP1423112B1/en
Priority to NZ530930A priority patent/NZ530930A/en
Priority to AT02760969T priority patent/ATE342720T1/de
Priority to US10/487,701 priority patent/US20050020571A1/en
Priority to PCT/SE2002/001507 priority patent/WO2003018009A1/en
Priority to AU2002326271A priority patent/AU2002326271B2/en
Priority to ZA200401550A priority patent/ZA200401550B/en
Priority to US11/936,244 priority patent/US20080108596A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SE0102855A 2001-08-27 2001-08-27 Method of treatment SE0102855D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0102855A SE0102855D0 (sv) 2001-08-27 2001-08-27 Method of treatment
AU2002326271A AU2002326271B2 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan
DE60215525T DE60215525T2 (de) 2001-08-27 2002-08-23 Kombination aus quetiapin und zolmitriptan
ES02760969T ES2274081T3 (es) 2001-08-27 2002-08-23 Combinacion de quetiapina y zolmitriptan.
JP2003522527A JP2005503391A (ja) 2001-08-27 2002-08-23 クエチアピンおよびゾルミトリプタンの配合物
CA002456480A CA2456480A1 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan
EP02760969A EP1423112B1 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan
NZ530930A NZ530930A (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan
AT02760969T ATE342720T1 (de) 2001-08-27 2002-08-23 Kombination aus quetiapin und zolmitriptan
US10/487,701 US20050020571A1 (en) 2001-08-27 2002-08-23 Combination of quetiapine and zolmitriptan
PCT/SE2002/001507 WO2003018009A1 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan
ZA200401550A ZA200401550B (en) 2001-08-27 2004-02-25 A combination of quetiapine and zolmitriptan.
US11/936,244 US20080108596A1 (en) 2001-08-27 2007-11-07 Combination of Quetiapine and Zolmitriptan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102855A SE0102855D0 (sv) 2001-08-27 2001-08-27 Method of treatment

Publications (1)

Publication Number Publication Date
SE0102855D0 true SE0102855D0 (sv) 2001-08-27

Family

ID=20285147

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102855A SE0102855D0 (sv) 2001-08-27 2001-08-27 Method of treatment

Country Status (12)

Country Link
US (2) US20050020571A1 (xx)
EP (1) EP1423112B1 (xx)
JP (1) JP2005503391A (xx)
AT (1) ATE342720T1 (xx)
AU (1) AU2002326271B2 (xx)
CA (1) CA2456480A1 (xx)
DE (1) DE60215525T2 (xx)
ES (1) ES2274081T3 (xx)
NZ (1) NZ530930A (xx)
SE (1) SE0102855D0 (xx)
WO (1) WO2003018009A1 (xx)
ZA (1) ZA200401550B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170123724A (ko) 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
US20110212980A1 (en) * 2008-10-22 2011-09-01 Novartis Ag Combinations for the treatment of migraine
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
US10457299B2 (en) * 2017-02-22 2019-10-29 Westinghouse Air Brake Technologies Corporation Train stop timer
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
GB9709815D0 (en) * 1997-05-14 1997-07-09 Merck Sharp & Dohme Therapeutic method
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
EP1423112A1 (en) 2004-06-02
ZA200401550B (en) 2004-11-17
DE60215525D1 (de) 2006-11-30
ATE342720T1 (de) 2006-11-15
NZ530930A (en) 2006-01-27
JP2005503391A (ja) 2005-02-03
US20080108596A1 (en) 2008-05-08
CA2456480A1 (en) 2003-03-06
US20050020571A1 (en) 2005-01-27
AU2002326271B2 (en) 2007-10-11
EP1423112B1 (en) 2006-10-18
WO2003018009A1 (en) 2003-03-06
DE60215525T2 (de) 2007-06-06
ES2274081T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
SE0104341D0 (sv) New use
ATE384058T1 (de) Thiazolderivate
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ATE457171T1 (de) Kombinationstherapie substituierter oxazolidinone
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
UA92000C2 (xx) Похідні 1-бензиліндол-2-карбоксаміду$производные 1-бензилиндол-2-карбоксамида
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
DE60209511D1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
DE60205455T2 (de) Naphthyridinderivate
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
HUP0101901A2 (hu) Gyógyászati készítmény nehezen kezelhető depresszió kombinált gyógyászati kezelésére, valamint kombinált kezelési eljárás
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
SE0102855D0 (sv) Method of treatment
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
HUP0303910A2 (hu) Húgyhólyagbetegségek kezelésére szolgáló kappa-opiát agonisták alkalmazása gyógyszerkészítmények előállítására
TNSN06151A1 (en) Nitrooxyderivatives of antihypertensive drugs
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
TW200509945A (en) Agent for treatment of anal disease